- Local governmentsCould allow greater investment in or expansion of physician‑affiliated hospitals and related facilities, which supporte…
- Targeted stakeholdersMay reduce regulatory constraints and compliance costs for physician groups and hospitals that seek to refer to or oper…
- Permitting processSupporters could argue it increases patient choice and competition by permitting more provider‑owned delivery models, w…
Patient Access to Higher Quality Health Care Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill (Patient Access to Higher Quality Health Care Act of 2025) would repeal sections 6001 and 10601 of the Patient Protection and Affordable Care Act and section 1106 of the Health Care and Education Reconciliation Act of 2010, restoring the prior law governing the Medicare exception to the prohibition on certain physician referrals for hospitals as if those provisions had never been enacted.
In other words, it would undo changes made by the 2010 health care reform laws to the statute that defines when physicians may refer Medicare patients to certain hospitals.
The text of the bill directs a straight repeal and restoration; it does not itself add new regulatory language or specify implementation details beyond that repeal.
On content alone the bill is narrowly focused and administratively implementable, which favors consideration. However, it repeals parts of landmark health‑care reform and lacks built‑in bipartisan compromise, offsets, or a phase‑in, making it politically contentious despite its technical form. Absent evidence of cross‑aisle dealmaking, a substantive fiscal analysis addressing Medicare cost impacts, or strong stakeholder alignment, the likelihood of becoming law is modest to low based solely on the bill text.
Relative to its intended legislative type, this bill is narrowly and clearly drafted to effect the repeal of specified sections of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act by restoring prior law, but it supplies very limited implementation, fiscal, and transitional detail.
Progressives emphasize risks to Medicare spending, conflicts of interest, and equity; conservatives emphasize deregulation, patient access, and physician investment.
Who stands to gain, and who may push back.
- Federal agenciesMay increase conflicts of interest and incentives for self‑referral, raising the risk of unnecessary services and highe…
- Targeted stakeholdersCritics may contend it weakens safeguards designed to prevent provider steering and could undermine care quality or equ…
- Federal agenciesCould increase enforcement and oversight challenges for federal regulators (CMS and DOJ) and heighten fraud and abuse r…
Why the argument around this bill splits.
Progressives emphasize risks to Medicare spending, conflicts of interest, and equity; conservatives emphasize deregulation, patient access, and physician investment.
From a mainstream progressive viewpoint, this bill is likely to be seen as rolling back an important reform enacted in 2010 that tightened limits on physician self-referral to hospitals.
Progressives would likely worry that the repeal reopens pathways for conflicts of interest and could increase unnecessary utilization and Medicare spending.
They would also be concerned about potential harms to equity and patient protections unless the bill included strong safeguards and oversight.
A pragmatic/centrist observer would treat the bill with caution and seek empirical evidence.
They would note that the bill simply restores pre‑2010 legal language and that the net effect depends on how providers respond and how CMS enforces existing fraud and abuse laws.
Centrists would want to weigh potential improvements in access or competition against risks to Medicare costs and quality, and would favor measured implementation with evaluation and guardrails.
A mainstream conservative view is likely to be broadly favorable.
Supporters would characterize the bill as removing an unnecessary regulatory restriction that limits physician autonomy and investment, and as restoring patient choice and competition that can improve access and quality.
Conservatives would emphasize reducing regulatory burdens and allowing market incentives to increase local health care capacity.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is narrowly focused and administratively implementable, which favors consideration. However, it repeals parts of landmark health‑care reform and lacks built‑in bipartisan compromise, offsets, or a phase‑in, making it politically contentious despite its technical form. Absent evidence of cross‑aisle dealmaking, a substantive fiscal analysis addressing Medicare cost impacts, or strong stakeholder alignment, the likelihood of becoming law is modest to low based solely on the bill text.
- No cost estimate or Congressional Budget Office score is included in the bill text; the magnitude and direction of any federal spending impact are therefore unknown.
- The bill text does not describe implementation timing, transitional rules, or regulatory guidance; administrative practicability and potential litigation risk are uncertain.
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Progressives emphasize risks to Medicare spending, conflicts of interest, and equity; conservatives emphasize deregulation, patient access,…
On content alone the bill is narrowly focused and administratively implementable, which favors consideration. However, it repeals parts of…
Relative to its intended legislative type, this bill is narrowly and clearly drafted to effect the repeal of specified sections of the Patient Protection and Affordable Care Act and the Health Care and Education Reconci…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.